Pharmaceutical Industry
Filter News
Found 15,391 articles
-
Researchers with the NYU School of Medicine and the University of Michigan identified a gene called ATDC that is necessary for the development of pancreatic cancer. They published their research in the journal Genes & Development.
-
A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020. It has seen success in animal models.
-
Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"
5/27/2019
Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ceftazidime/sodium chloride injection" jointly developed by the Group and its associated company Beijing Ruiye Drugs Manufacture Co.
-
Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss
5/27/2019
This agreement defines an exclusive option to obtain licences for joint programs including Otoferlin & Usher Type 1 and preference rights on the research pipeline in the field of genetic disorders of the inner ear in order to set up future collaborations
-
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science
5/26/2019
Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future
-
Company Statement: Teva Reaches Agreement with State of Oklahoma to Resolve State’s Claims Against the Company
5/26/2019
Teva Pharmaceuticals USA and related affiliates of Teva Pharmaceutical Industries Ltd., and the state of Oklahoma, have entered into an agreement for a one-time payment of $85 million to the state.
-
Heritage Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) as a result of a sterility test failure
5/25/2019
Heritage Pharmaceuticals Inc. East Brunswick, New Jersey, is initiating a voluntary recall of Amikacin Sulfate Injection, USP, 1g/4 mL, Lot: VEAC025, Expiry Date: October 2019 and Prochlorperazine Edisylate Injection, USP, 10mg/2mL, Lot: VPCA172, Expiry Date: April 2020, to the consumer level.
-
Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.
-
The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.
-
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
-
On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.
-
Research Roundup for Friday, May 24.
-
New York City-based Tonix Pharmaceuticals announced it has in-licensed a Phase II drug, TNX-1300, from Columbia University. TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine abusers.
-
BioSpace Movers and Shakers, May 24
5/24/2019
Biopharma companies from across the globe strengthen their leadership teams with key executive appointments. -
MorphoSys to Present at Upcoming June 2019 Investor Conferences
5/24/2019
MorphoSys AG will present at the following conferences
-
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
5/24/2019
Full Results from Phase 3 ARTEMIS Study Will Be Featured
-
FLX Bio Announces Name Change to RAPT Therapeutics
5/24/2019
Name Reflects Our Focus on Defeating Cancer and Allergic Inflammatory Diseases
-
Alpine Immune Sciences to Present at Upcoming Investor Conferences
5/24/2019
Alpine Immune Sciences, Inc. announced the company will participate in three upcoming investor conferences in June.
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
5/24/2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.
-
Lannett Announces CFO Retirement
5/24/2019
Lannett Company, Inc. announced that the company's chief financial officer, Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K for fiscal year 2019.